MediXall Group, Inc.
MDXL · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 422.1% | 295.3% | – | – |
| Cost of Goods Sold | $0 | $3 | $3 | $3 |
| Gross Profit | $0 | -$3 | -$3 | -$3 |
| % Margin | 23.6% | -5,296.2% | -20,349.5% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $4 | $6 | $6 | $5 |
| SG&A Expenses | $4 | $6 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $1 |
| Operating Expenses | $4 | $0 | $6 | $6 |
| Operating Income | -$4 | -$7 | -$7 | -$6 |
| % Margin | -1,265.6% | -11,035.2% | -43,561.3% | – |
| Other Income/Exp. Net | -$1 | -$0 | $0 | -$1 |
| Pre-Tax Income | -$5 | -$7 | -$6 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$7 | -$6 | -$6 |
| % Margin | -1,474.8% | -11,524.6% | -40,245.8% | – |
| EPS | -0.037 | -0.061 | -0.058 | -0.066 |
| % Growth | 38.9% | -5.7% | 11.6% | – |
| EPS Diluted | -0.037 | -0.061 | -0.058 | -0.066 |
| Weighted Avg Shares Out | 127 | 117 | 104 | 91 |
| Weighted Avg Shares Out Dil | 127 | 117 | 104 | 91 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$7 | -$6 | -$6 |
| % Margin | -1,254.6% | -11,006.9% | -40,835.9% | – |